Journal
PHARMACEUTICALS
Volume 15, Issue 12, Pages -Publisher
MDPI
DOI: 10.3390/ph15121560
Keywords
Alzheimer's disease; pathogenesis; pharmacotherapy; multi-target ligands; polypharmacology
Categories
Funding
- International Medical University (IMU), Malaysia through IMU Internal Research Grant [MAPC I-2022 (02)]
Ask authors/readers for more resources
Alzheimer's disease is a neurodegenerative disorder with complex pathophysiology. Current treatment mainly focuses on symptom relief. Due to the multifactorial origin of the disease, multi-target strategies have been proposed. This review provides an overview of the pathogenesis of Alzheimer's disease, current drug therapies, and the rationale and examples of multi-target drugs.
Alzheimer's disease (AD) is a neurodegenerative disorder characterized by decreased synaptic transmission and cerebral atrophy with appearance of amyloid plaques and neurofibrillary tangles. Cognitive, functional, and behavioral alterations are commonly associated with the disease. Different pathophysiological pathways of AD have been proposed, some of which interact and influence one another. Current treatment for AD mainly involves the use of therapeutic agents to alleviate the symptoms in AD patients. The conventional single-target treatment approaches do not often cause the desired effect in the disease due to its multifactorial origin. Thus, multi-target strategies have since been undertaken, which aim to simultaneously target multiple targets involved in the development of AD. In this review, we provide an overview of the pathogenesis of AD and the current drug therapies for the disease. Additionally, rationales of the multi-target approaches and examples of multi-target drugs with pharmacological actions against AD are also discussed.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available